Candel Therapeutics, Inc.CADL

$8.31+0.32 (+4.01%)

NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap

$518M

Small-cap

+206%

2021 — today

10-Year Price

+22%

2021 — today

52-Week Range

$4.42$9.27

Current $8.31· 80%

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.

Valuation in context

P/E ratio

-8.5

N/A

Not meaningful — company is unprofitable

P/B ratio

3.8

Above average

Pricier than usual over the last 10 years

FCF Yield

-9.5%

Historically high

Historically high relative to the last 10 years

Free · No credit card needed

Get alerted when CADL is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.